APN01, alunacedase alfa, soluble ACE2, RhACE2-APN01 for COVID-19

APN01, alunacedase alfa, soluble ACE2, RhACE2-APN01 has been reported as potentially beneficial for treatment of COVID-19. We have not reviewed these studies. See all other treatments.

APN01, alunacedase alfa, soluble ACE2, RhACE2-APN01 Submit Updates

Wirnsberger et al., Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants, bioRxiv, doi:10.1101/2021.09.10.459744

AbstractThe recent emergence of multiple SARS-CoV-2 variants has caused considerable concern due to reduced vaccine efficacy and escape from neutralizing antibody therapeutics. It is therefore paramount to develop therapeutic strategies that inhibit all known and future SARS-CoV-2 variants. Here we report that all SARS-CoV-2 variants analyzed, including variants of concern (VOC) Alpha, Beta, Gamma, and Delta, exhibit enhanced binding affinity to clinical grade and phase 2 tested recombinant human soluble ACE2 (APN01). Importantly, soluble ACE2 neutralized infection of VeroE6 cells and human lung epithelial cells by multiple VOC strains with markedly enhanced potency when compared to reference SARS-CoV-2 isolates. Effective inhibition of infections with SARS-CoV-2 variants was validated and confirmed in two independent laboratories. These data show that SARS-CoV-2 variants that have emerged around the world, including current VOC and several variants of interest, can be inhibited by soluble ACE2, providing proof of principle of a pan-SARS-CoV-2 therapeutic.

Shah et al., Peptides-based therapeutics: Emerging potential therapeutic agents for COVID-19, Therapies, doi:10.1016/j.therap.2021.09.007

Angeli et al., The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: One year later, European Journal of Internal Medicine, doi:10.1016/j.ejim.2021.09.007

Lundstrom et al., COVID-19 signalome: Potential therapeutic interventions, Cellular Signalling, doi:10.1016/j.cellsig.2022.110559

Talukder et al., Drugs for COVID-19 Treatment: A New Challenge, Applied Biochemistry and Biotechnology, doi:10.1007/s12010-023-04439-4

Raghav et al., Potential treatments of COVID-19: Drug repurposing and therapeutic interventions, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

https://clinicaltrials.gov/ct2/show/NCT04335136

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0